Compare PHGE & BGLC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PHGE | BGLC |
|---|---|---|
| Founded | 2015 | 2017 |
| Country | United States | Malaysia |
| Employees | 20 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7M | 4.4M |
| IPO Year | N/A | 2019 |
| Metric | PHGE | BGLC |
|---|---|---|
| Price | $0.20 | $1.63 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 1.2M | 12.2K |
| Earning Date | 05-15-2026 | 04-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 45.78 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $7,424,911.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.19 | $1.07 |
| 52 Week High | $8.50 | $8.98 |
| Indicator | PHGE | BGLC |
|---|---|---|
| Relative Strength Index (RSI) | 26.06 | 33.82 |
| Support Level | N/A | $1.55 |
| Resistance Level | $0.65 | $2.15 |
| Average True Range (ATR) | 0.02 | 0.11 |
| MACD | 0.02 | -0.02 |
| Stochastic Oscillator | 4.58 | 14.02 |
BiomX Inc is a company focused on acquiring and further developing technologies that identify, track, and counter physical threats across defense, security, critical infrastructure, and first-response sectors. The Company's portfolio is built around the growing need for earlier and more accurate threat detection, particularly as UAVs and other autonomous systems play a larger role in defense and homeland security.
BioNexus Gene Lab Corp is a Wyoming corporation with two principal operating subsidiaries in Malaysia: Chemrex Corporation Sdn. Bhd. (Chemrex) and MRNA Scientific Sdn. Bhd. (MRNA Scientific). Chemrex is engaged in the distribution of chemical raw materials, mainly for industrial applications in Southeast Asia. MRNA Scientific is engaged in the development and provision of blood-based genomic screening services intended to support early disease risk assessment and health management. Trading of industrial chemicals- Includes trading of industrial chemicals. Provision for genomic screening services- includes in commercializing proprietary blood-based diagnostic test for early disease detection. Investment holding- Investment holding, are its segments.